SIOX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SIOX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sio Gene Therapies's shares outstanding for the quarter that ended in Dec. 2022 was 73.98 Mil.
Sio Gene Therapies's quarterly shares outstanding stayed the same from Sep. 2022 (73.98 Mil) to Dec. 2022 (73.98 Mil).
Sio Gene Therapies's annual shares outstanding increased from Mar. 2021 (69.38 Mil) to Mar. 2022 (73.74 Mil). It means Sio Gene Therapies issued new shares from Mar. 2021 to Mar. 2022 .
The historical data trend for Sio Gene Therapies's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sio Gene Therapies Annual Data | |||||||||||||||||
Trend | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | |||||||||
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 13.47 | 22.78 | 39.53 | 69.38 | 73.74 |
Sio Gene Therapies Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 73.70 | 73.74 | 73.98 | 73.98 | 73.98 |
For the Biotechnology subindustry, Sio Gene Therapies's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Sio Gene Therapies's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Sio Gene Therapies (OTCPK:SIOX) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of Sio Gene Therapies's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Parag V Meswani | officer: Chief Commercial Officer | 130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036 |
Pavan Cheruvu | officer: Chief Executive Officer | C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Kristiina Md Vuori | director | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
David W. Nassif | officer: Principal Financial Officer | C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583 |
Senthil Vel Sundaram | director | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
Dexxon Holdings Ltd. | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 30600000 |
Andrew Lo | 10 percent owner | C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
Svf Investments (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET, LONDON X0 W1K3JP |
Patrick Machado | 10 percent owner | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Qvt Associates Gp Llc | 10 percent owner | 1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036 |
Viking Global Performance Llc | 10 percent owner | 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
From GuruFocus
By Marketwired Marketwired • 10-04-2021
By Marketwired Marketwired • 05-19-2021
By Marketwired Marketwired • 03-11-2021
By PurpleRose PurpleRose • 08-11-2022
By Marketwired Marketwired • 02-04-2021
By GlobeNewswire GlobeNewswire • 10-21-2021
By Don Li2 Don Li2 • 11-11-2021
By Marketwired Marketwired • 10-04-2021
By Value_Insider Value_Insider • 12-14-2022
By Marketwired Marketwired • 01-04-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.